Homatropine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Myanmar prescribing information.

Generic Medicine Info

Indications and Dosage

Ophthalmic
Mydriasis and cycloplegia for refraction

Adult: As homatropine hydrobromide 2% or 5% solution: Instill 1-2 drops into affected eye(s) immediately before the procedure, repeat after 5-10 minutes if necessary.
Child: >3 months As homatropine hydrobromide 2% solution: Instill 1 drop into affected eye(s) immediately before the procedure, repeat after 10 minutes if necessary.

Ophthalmic
Uveitis

Adult: As homatropine hydrobromide 2% or 5% solution: Instill 1-2 drops into affected eye(s) bid or tid, or up to 3-4 hourly as needed.
Child: >3 months As homatropine hydrobromide 2% solution: Instill 1 drop into affected eye(s) bid or tid.

Contraindications

Primary glaucoma, narrow anterior chamber angle glaucoma.

Special Precautions

Patient with keratoconus, down syndrome, brain damage, exposed to high environmental temperature. Children. Pregnancy and lactation.

Adverse Reactions

Significant: Fixed dilated pupil, increased ocular pressure; light sensitivity, hyperthermia.
Eye disorder: Transient stinging, burning sensation, irritation, follicular conjunctivitis, exudates, mydriasis, ocular hyperaemia, vascular congestion, blurred vision.
Gastrointestinal disorders: Dry mouth.
Metabolism and nutrition disorders: Oedema.
Psychiatric disorders: Drowsiness, somnolence.
Skin and subcutaneous tissue disorders: Eczemetoid dermatitis.

Pregnancy Category (US FDA)

Ophth/PO: C

Patient Counseling Information

This drug may cause drowsiness, blurred vision and sensitivity to light, if affected, do not drive or operate machinery. Remove contact lenses prior to ophthalmic administration and reinsert after 15 minutes.

Overdosage

Symptoms: Flushing, dry skin, rash, blurred vision, rapid/irregular pulse, hypertension, hyperpyrexia, fever, abdominal distention, convulsions, hallucinations, loss of neuro-muscular coordination, CNS depression, circulatory and respiratory failure, paralytic ileus, confusion, psychoses, agitation, delusions, delirium, paranoia, tachycardia, dysrhythmias, seizures, coma, death. Management: Symptomatic and supportive therapy. Maintain a patent airway and assist respiration, if necessary. Keep body surface of infant and children moist.

Drug Interactions

Enhanced antimuscarinic effect with amantadine, antihistamines, phenothiazine, antipsychotics, and TCA.

Action

Description: Homatropine is an antimuscarinic tertiary amine that blocks the responses of the iris sphincter muscle and the accommodative ciliary muscle from cholinergic stimulation, thus producing pupillary dilatation and paralysis of accommodation.
Onset: Within 30-60 minutes.

Chemical Structure

Storage

Store below 25°C. Protect from light.

MIMS Class

Mydriatic Drugs

ATC Classification

S01FA05 - homatropine ; Belongs to the class of anticholinergics used as mydriatics and cycloplegics.

References

Anon. Homatropine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 08/01/2018.

Buckingham R (ed). Homatropine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/01/2018.

Homatropine Hydrobromide Ophthalmic Solution (Ocusoft, Inc). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 08/01/2018.

Joint Formulary Committee. Homatropine Hydrobromide. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 08/01/2018.

McEvoy GK, Snow EK, Miller J et al (eds). Homatropine Hydrobromide (EENT). AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 08/01/2018.

Pharmaco NZ Ltd. Isopto Eye Drops 2% data sheet July 2014. Medsafe. http://www.medsafe.govt.nz/. Accessed 12/01/2018.

Disclaimer: This information is independently developed by MIMS based on Homatropine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com